What that means for biopharmaceutical firms, said Palo Alto, California lawyer Antoinette Konski, a partner with Foley & Lardner, is likely an increase in rejections by the US PTO of patent claims under the boundaries of Section 101 of the US Patent Act,…
written on 10.03.2014
US Capitol Capsule: Patent rejections expected to rise under post-Myriad guidelines
